about
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Improving identification of lynch syndrome patients: a comparison of research data with clinical records.Barriers and motivators for referral of patients with suspected lynch syndrome to cancer genetic services: a qualitative studyKnowledge, attitudes and referral patterns of lynch syndrome: a survey of clinicians in australiaTumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.RANKL/RANK control Brca1 mutation-driven mammary tumors.Cadherin-11 expression is upregulated in invasive human breast cancer.Gender differences in risk factors for coronary heart disease.Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling.Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.Identification and management of familial breast cancer in Austria.Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.Endometrial cancer risk and survival by tumor MMR status.Reply to J. Moline et alImproving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual toolAssociation between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patientsDifferential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast CancerFine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
P50
Q30252854-FAB3B2D3-586B-4015-A594-D0275EBBB351Q30580847-452B4460-6334-43BF-A58E-F5486A8C3D0BQ34608805-F370F39D-16B4-4141-BB47-5916B352D21CQ34683932-5E69C5E2-E3E5-4C6C-A93D-A851DF644FCFQ35063442-5F9E686C-471E-404E-BB9C-B853193A146FQ36178189-88A2FECC-0790-4393-8539-8326540FEB0CQ36295269-5D13B4DB-D8F0-4388-822C-E0578D89397AQ36356727-B1142CFF-5BD4-47E2-9659-79F21BE81BCEQ37457304-F42B8F6C-65DC-4958-B2D1-F5FAD19BFD6BQ37581797-26C0AA2C-A58F-4A9F-A8AB-725CAD64E070Q37629321-02108652-C302-4018-A7F1-3B4E0C8F6B2DQ38717239-140EEE47-3BE8-4A67-8A4C-0860FAEF4E43Q40077748-D84560C4-F099-44AE-801B-02A1FED383A4Q42363605-1490A5BC-8E84-405A-959F-AC865C9A6BFDQ46103372-A798557D-3B92-495E-B1F2-84C67759551BQ47147531-820207FA-F729-4667-A07D-AEB4F85E5490Q48262377-57897357-A1E3-426D-BBFE-B7C4C4D9D563Q49024646-97CE6109-A278-4380-B8BA-982A0659795EQ49488966-581C8E03-6B5C-4782-A24B-8CD0DD87E7D6Q52796711-ACC48493-7185-4D76-9678-E111086CA680Q54986102-F54449CD-540E-4FA7-AA4F-1EEE342EE043Q57306037-261D89FB-C907-4102-906A-969E8B6FB2ABQ57930243-59340E80-479B-4EEE-BF0D-6DB803DBDA5FQ64075313-C7DF234A-0B16-4B9B-B5B6-BF3145B92496Q91125266-A209D91B-FB75-4D5F-90A2-ED9930E56CD9Q92480972-60420822-10E3-422D-B06E-659B850F35AC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yen Y Tan
@ast
Yen Y Tan
@en
Yen Y Tan
@es
Yen Y Tan
@nl
type
label
Yen Y Tan
@ast
Yen Y Tan
@en
Yen Y Tan
@es
Yen Y Tan
@nl
prefLabel
Yen Y Tan
@ast
Yen Y Tan
@en
Yen Y Tan
@es
Yen Y Tan
@nl
P106
P31
P496
0000-0003-1063-5352